In the context of lung cancer, significantly more gene mutation events, including mutations in CD74 (p < 0.001), EGFR (p = 0.019), MYC (p = 0.045), GNAS (p = 0.025), RET (p = 0.019), TET2 (p = 0.044), CIITA (p = 0.009), KIF5B (p = 0.003), VEGFB (p = 0.01), and ZNF217 (p = 0.017), occurred in patients with NRG1 fusions (Fig. 3c). This evidence concerns the gene VEGFB and lung cancer.